DGAP-News

Aladdin Healthcare Technologies discovers anti-osteoporosis nanomolar activity leads from natural compounds dataset with its Deep Learning Algorithms for drug discovery, validated by leading scientific publication 'European Journal of Medicinal Chemistry' - Seite 2

Aladdin's pre-trained deep learning method (P-SAMPNN) confirmed 5 from 10 selected hits through virtual screening of the natural products contained in the library. Among the confirmed hits, 2 compounds (AP-123/40765213 and AE-562/43462182) were actually the nanomolar inhibitors against osteoclastogenesis with a new scaffold. This work has proved that by integrating deep learning approaches with wet biological and chemical processes, the Pre-trained Self-Attentive Message Passing Neural Network (P-SAMPNN) is capable of expediting the drug discovery process and identifying nanomolar activity leads.

Wade Menpes-Smith, CEO of Aladdin Healthcare Technologies SE, comments: "The further validation of our innovative pre-trained deep learning model shows the high-end AI-technology capability of Aladdin. Validation processes proved that the P-SAMPNN model is significantly superior to other baseline models. By reaching this key milestone, we are continuing our path towards further breakthroughs in AI drug discovery."

Already in July this year, Aladdin announced the development of a new deep learning method for drug discovery with a superior performance, which was validated by the International Joint Conference on Artificial Intelligence (IJCAI), a world-leading organization for scientific purpose with focus on Artificial Intelligence (AI).

About Aladdin Healthcare Technologies SE
Aladdin Healthcare Technologies SE (and its wholly owned subsidiary Aladdin Healthcare Technologies Ltd.) is a leading developer of AI healthcare diagnostics and drug discovery applications that can accelerate both early stage disease diagnosis and the end-to-end drug discovery process. Aladdin targets age-related diseases including a significant focus on Alzheimer's disease. Aladdin accomplishes this by collaborating with numerous partners within the global healthcare ecosystem to confidentially and securely gather targeted data including genome, tabular, MRI, PET, cognition and other lifestyle data. These datasets are then analysed by our award-winning AI team and used to develop proprietary AI tools that can assist healthcare professionals to more accurately and efficiently diagnose age-related diseases. This new diagnostic process will save significant time and costs for healthcare professionals. Additionally, our AI drug discovery platform will be used by pharmaceutical Companies to speed up drug development, clinical trials and predict outcomes more accurately.